Oncoinvent - årsrapport 2021, 34 pasienter dosert - 0 bivirkning
AksjeInvest
20.05.2022 kl 16:32
727
Noen som har hørt noe fra dette arrangementet?
Oncoinvent AS, a clinical stage company advancing a pipeline of radiopharmaceutical products across a variety of solid cancers, today announced that members of management will present at the Guggenheim Radiopharmaceuticals Day on Tuesday, May 17, 2022 in New York, NY.
Oslo, Norway 10, May 2022
Details are as follows:
• Company panel discussion together with Point Biopharma, Fusion Pharmaceuticals, Aktis Oncology and Curie Therapeutics on Tuesday, May 17, 2022 at 1:30 p.m. ET.
• Fireside chat with Charles Zhu, Vice President Guggenheim Securities LLC on Tuesday, May 17, 2022 at 4:30 p.m. ET.
Oncoinvent AS, a clinical stage company advancing a pipeline of radiopharmaceutical products across a variety of solid cancers, today announced that members of management will present at the Guggenheim Radiopharmaceuticals Day on Tuesday, May 17, 2022 in New York, NY.
Oslo, Norway 10, May 2022
Details are as follows:
• Company panel discussion together with Point Biopharma, Fusion Pharmaceuticals, Aktis Oncology and Curie Therapeutics on Tuesday, May 17, 2022 at 1:30 p.m. ET.
• Fireside chat with Charles Zhu, Vice President Guggenheim Securities LLC on Tuesday, May 17, 2022 at 4:30 p.m. ET.
AksjeInvest
07.06.2022 kl 23:48
499
Vi har gleden av å informere deg om at vi sent fredag ettermiddag mottok utslippstillatelse for Radon fra Direktoratet for strålevern og atomsikkerhet som vi har ventet på for å kunne produsere vår ledende produktkandidat Radspherin®. Vi har allerede startet de nødvendige forberedelsene for å oppstart av produksjonen av Radspherin® for de pågående kliniske studier, og vi håper å starte rekrutteringen av pasienter på nytt i nær fremtid.